smpc semaglutide and Cardiovascular Outcomes in Obesity without Diabetes Semaglutide for weight loss |
Description
Acknowledgements This review article did not warrant ethical approval and no funding was received
Semaglutide is available as a once-weekly injection
Notably, GLP-1 and GIP/GLP-1 hybrid drugs are now clinically employed for diabetes and obesity, whereas GLP-2 drugs are used in the clinic to treat short bowel syndrome
Some people also report a slight headache or mild fatigue in the first week
Pre-Existing Conditions If you have diabetes, thyroid disorders, or any endocrine-related condition, careful monitoring may be needed because sermorelin can affect hormone balance
